Company / Working Capital
Tvardi Therapeutics, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$39.9M
FY2024
5-year range
$39.9M / $176.6M
FY2020-FY2024
Trend
-56.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $177M in FY2020 to $40M in FY2024.
Based on SEC 10-K filings.
$40M in FY2024 with a 5-year CAGR of -20.1%.
Declined from $145M to $40M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -36.5%
- 5-Year CAGR
- -20.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Tvardi Therapeutics, Inc.'s working capital has declined for 4 consecutive years.
- 5-year CAGR of -20.1%, indicating a declining trend.
- In FY2024, working capital decreased 56.0% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $39.9M | -56.0% |
| FY2023 | $90.6M | -37.7% |
| FY2022 | $145.5M | -6.6% |
| FY2021 | $155.7M | -11.8% |
| FY2020 | $176.6M | +43.8% |
| FY2019 | $122.8M | -3.9% |
| FY2018 | $127.7M | +47.5% |
| FY2017 | $86.6M | +73.4% |
| FY2016 | $49.9M | -51.9% |
| FY2015 | $103.7M | +108.4% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026